After years of out-licensing, product sales and whatever else it took to float the sinking AstraZeneca ship, CEO Pascal Soriot is now a buyer. And he's going big.
Thursday night, Soriot announced that AstraZeneca is paying Daiichi Sankyo $1.35 billion upfront to partner on trastuzumab deruxtecan, an antibody drug conjugate for HER2 expressing cancers. Half arrives with the signing, the other half in a year. And Soriot is adding up to $5.55 billion more in development and commercial milestones, for a total of $6.9 billion, one of the largest pacts the company has ever struck.
Pascal Soriot in Washington, DC, February 2019 Getty
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription